- A + HIGH CONTRAST TURN ON TEXT TO SPEECH HOME ABOUT US PIPELINE TECHNOLOGY INVESTORS NEWS&MEDIA CONTACT & ACCESS > NEWS&MEDIA > PRESS RELEASES Press releases 2016-10-13 / Press release GenSight Biologics reports its cash position as of September 30, 2016 DOWNLOAD 2016-09-08 / Press release GenSight Biologics receives approval to include teenage patients in RESCUE and REVERSE Phase III trials with GS010 in Leber’s Hereditary Optic Neuropathy DOWNLOAD 2016-09-01 / Press release The European Medicines Agency (EMA), has granted orphan drug designation (ODD) to the Company’s product candidate GS030 for the treatment of retinitis pigmentosa. DOWNLOAD 2016-08-11 / Press release GenSight Biologics confirms the success of its IPO by exercising 88.9% of the over-allotment option. DOWNLOAD 2016-08-11 / Press release GenSight Biologics announces the implementation of a liquidity contract with Oddo & Cie DOWNLOAD 2016-08-11 / Press release Total size of the offering in the context of the Company’s IPO increased to 5,655,859 new shares, i.e. €45.2 million. DOWNLOAD 2016-07-13 / Press release GenSight Biologics announces successful IPO on Euronext Paris : €40 million raised, largest French biotech IPO YTD. DOWNLOAD 2016-07-05 / Press release GenSight Biologics launches its Initial Public Offering on the regulated market of Euronext in Paris. DOWNLOAD 2016-06-08 / Press release Confirmation of the good safety and tolerability profile of GS010 and improvement of visual acuity in patients with an onset of disease of less than 2 years. DOWNLOAD 2016-05-24 / Press release GenSight Biologics announces the registration of its document de base in relation to its planned IPO on Euronext's regulated market in Paris. DOWNLOAD 2016-02-29 / Press release GenSight Biologics announced enrollment of the first patient in both RESCUE and REVERSE, two pivotal Phase III trials with lead product candidate GS010. DOWNLOAD 2015-09-10 / Press release GenSight Biologics announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) Application for two Phase III clinical trials of GS010. DOWNLOAD 2015-07-23 / Press release GenSight Biologics announced that it has completed a Series B preferred stock financing of approximately $36 million. DOWNLOAD 2015-07-06 / Press release GenSight Biologics Appoints Thomas Gidoin as Chief Financial Officer & Michael Wyzga to Board of Directors. DOWNLOAD 2015-01-06 / Press release GenSight Biologics, Pixium Vision and Fondation Voir et Entendre join forces and benefit from a total €18.5 million funding for SIGHT AGAIN as part of the Investment for the Future. DOWNLOAD 2014-05-06 / Press release GenSight Biologics announces the appointment of Jean-Philippe Combal as Chief Operating Officer. DOWNLOAD 2013-04-08 / Press release GenSight Biologics announced today the closing of a €32 million Series A financin for Ophthalmic Gene Therapy. DOWNLOAD PRESS RELEASES EVENTS HOME ABOUT US Company Scientific Founders Management Board Scientific advisory board Partners PIPELINE Leber Hereditary Optic Neuropathy (LHON) Retinitis Pigmentosa (RP) Geographic Atrophy in Dry-AMD Clinical trials TECHNOLOGY Gene Therapy Mitochondrial Targeting Sequence (MTS) Optogenetics INVESTORS Welcome ! Stock data Press releases News room Documentation Contact NEWS&MEDIA Press releases Events CONTACT & ACCESS ©2015-2016 Gensight Biologics Terms of Use Sitemap Gensight Biologics 74, rue du Faubourg Saint-Antoine 75012 Paris, FRANCE Phone: +33 1 76 21 72 20 infos@gensight-biologics.com